FATE News and Press, Fate Therapeutics Inc. From 03/28/22

The SPDR S&P Biotech ETF is down close to 25% year-to-date but Michael Yee sees several names in this space that look promising at current valuations. Why did XBI recover in recent weeks? Interestingly, XBI is down by that much despite a 10% rebound over the past two wee...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q4-2021 13F filings the consensus holdings were updated, 7 stocks were removed and 7 added from the unive...

The bloodbath for Cathie Wood’s ARK Innovation ETF (NYSEARCA:ARKK) continues, despite the fund being up slightly on Thursday. Wood’s ETF is -36% YTD and is currently working towards its fifth straight downward month. Meanwhile, this week has been particularly difficult...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q4-2021 13F filings the consensus holdings were updated, 7 stocks were removed and 7 added from the unive...

The Ark Innovation ETF was fallen 60% from its high water mark, far more than 10%ish drop of the handful of growth stocks which top the S&P 500 and NASDAQ100. Charts and tables for price and AUM show clearly the the majority of investors in ARKK bought at the top; most ARKK holder...

Lone Pine Capital’s 13F portfolio value decreased from $29.68B to $24.41B. The number of positions decreased from 39 to 29. They increased Amazon, RH, NetEase, Confluent, and Marqeta while reducing Block and dropping Moderna and Meta Platforms. The top three positions are A...

SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, t...

Fate Therapeutics, Inc. (FATE) Q4 2021 Earnings Conference Call February 28, 2022 17:00 ET Company Participants Scott Wolchko - President and Chief Executive Officer Wayne Chu - Chief Medical Officer Ed Dulac - Chief Financial Officer Bob Valamehr - Chief Research and Development Officer Conf...

Fate Therapeutics press release (NASDAQ:FATE): Q4 GAAP EPS of -$0.72 misses by $0.04. Revenue of $17.07M (+7.4% Y/Y) beats by $5.52M. For further details see: Fate Therapeutics GAAP EPS of -$0.72 misses by $0.04, revenue of $17.07M beats by $5.52M

Enrollment Ongoing in Multi-dose, Multi-cycle Escalation Cohort of FT596+R at 900 Million Cells per Dose for R/R BCL; Interim Phase 1 Data of 16 Patients Showed 69% ORR and 56% CR in Single-dose Escalation Cohorts of FT596+R at ≥90 Million Cells Granted RMAT Designation f...